The US government has made a significant change by reclassifying marijuana from a high-risk category that included drugs like heroin and LSD to a lower-risk group. This adjustment is crucial for the cannabis industry, which has faced numerous challenges due to its previous classification. Cannabis was legal in many states, yet federally it was deemed to have no medical value, complicating business operations with heavy taxes and limited banking access. The reclassification could alleviate some of these pressures, allowing cannabis businesses to manage finances more effectively. However, marijuana remains illegal federally for recreational use, and states will continue to set their own regulations, leading to inconsistencies across the country. This shift highlights the federal government’s gradual alignment with changing public opinion and state laws regarding cannabis, raising questions about future regulatory changes.